Access
To read this story in full you will need to login or make a payment (see right).
News Feature
Nature 435, 138 (12 May 2005) | doi:10.1038/435138a; Published online 11 May 2005
Open Innovation Challenges
-
Protect Enzyme from In Planta Degradation
A proposal for stable expression of an enzyme in corn seed is desired.
-
Efficient Chromosome Doubling: Plant Cell Division
The Seeker is looking for an efficient chromosome doubling method in plants and in particular, metho...
- More Challenges
- Powered by:
nature jobs
Research Psychiatrist
- Scripps Research Institute
- La Jolla, CA
Laboratory Manager / Principal Research Assistant
- Wellcome Trust Sanger Institute
- Hinxton, Cambridge, CB10 1SA, UK
Chinese clinical trials: Consenting adults? Not necessarily...
David Cyranoski1
- David Cyranoski is Nature's Asian-Pacific correspondent.
Abstract
Companies and scientists in the West are keen to test their drugs in China, which is an important future market. But those running clinical trials need to be on their guard, says David Cyranoski.
In October 2003, China became the first country to move gene therapy into the medical mainstream, when it approved for general clinical use a treatment for head and neck squamous cancer. The feat was a symbol of the country's biomedical ambitions, and was lauded in the Chinese media.
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Both a ?magic bullet? and good aim are required to link public health interests and health care needs in HIV infectionNature Medicine News and Views (01 Mar 2000)
